. Then a comparison of glyburide and insulin in women with gestational diabetes mellitus was done 8 . The results of which showed there were no significant differences in mean neonatal glucose concentrations, macrosomia, neonatal intensive care unit (NICU) admission, or fetal anomalies( The metformin use in pregnancy was also scrutinized critically as metformin was shown to be able to significantly cross the placenta, with fetal concentrations in the range of half of maternal concentrations 15 .However, it does not stimulate insulin secretion or release, and does not cause hypoglycemia. Metformin enhances insulin action, stimulating glucose uptake in the liver and in the periphery and also suppressing hepatic glucose output. It is also useful in the insulin resistance syndrome and constitute an increasingly popular treatment for polycystic ovarian syndrome, often inducing ovulation and resulting in pregnancy. Several trials did not report any major congenital malformations in infants born to mothers who received metformin throughout pregnancy, whether those mothers were diabetics 16, 17 or non diabetics 18 . Several studies in South Africa more than 20 years ago 19, 20 and in New Zealand in 2006 21 reported no adverse pregnancy outcomes. The problem was that the studies were small, retrospective and non-randomised. So we need to know what are the long term effects of exposing the fetus to metformin?. The largest trial of metformin against insulin ,popularly known as MiG study is completed and the results of which are published. 22 . It would therefore seem that there is a place for the use of metformin in the management of gestational diabetes. The loss of weight from enrolment to the postpartum visit was 8.1±5.1 kg in the metformin group and 6.9±5.3 kg in the insulin group and this difference is highly significant p<0.006. Metformin reduces pregnancy-associated weight gain compared with the alternatives.There was no excess of neonatal hypoglycaemia in the metformin group or of respiratory distress syndrome, birth trauma, or low Apgar scores. There were no significant differences in rates of birthweight below the tenth or abovethe 90th centile or in any of the neonatal anthropometry measurements. Cord blood serum insulin concentrations were slightly higher at 50 pmol/L in the metformin group versus 40 pmol/L in the insulin group but this difference was not significant. A MEDLINE search (1966 ( -March 2007 showed oral antidiabetic agents in pregnancy and lactation is on way of paradigm shift 23 . It showed neither glyburide nor metformin has caused developmental toxicity in humans. Glyburide has been used for the treatment of gestational diabetes, and metformin has been used in women with PCOS who eventually became pregnant.
The available data suggest that glyburide and metformin are not teratogenic in humans when used in clinically recommended doses. The data also suggest that glyburide may be sed for the treatment of gestational diabetes in some women, while metformin may be used safely for ovulation in women with PCOS. Metformin, glyburide, and glipizide appear to be compatible with breast-feeding. Randomized controlled trials will better elucidate the benefit of glyburide, metformin, and thiazolidinediones in pregnancy and over the long-term. Such data on the use of OAAs in pregnancy are shifting the paradigm that once stated that they should never be used in pregnancy. This shift may be welcome to women with gestational diabetes who are inconvenienced by injections and to those in areas where insulin may not be readily available or is cost prohibitive. With the growing rates of diabetes, especially in the developing world, such a shift in paradigm may be greatly appreciated
Conclusion:
There is evidence that good results can be achieved with OHAs providing that euglycemia targets are achieved. The ease of education and management of these selected pregnant diabetic patients make the use of OHAs an attractive option, especially in a poorly resourced environment. But there are notable limitations to the current literature. First, there are possible publication bias. Though published and unpublished studies show no differences between groups-this is due to small groups included in the studies.
Large group studies are needed to delineate the real picture.
